ProfileGDS5678 / 1430040_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 39% 54% 39% 38% 39% 38% 50% 39% 47% 39% 39% 37% 38% 38% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9323439
GSM967853U87-EV human glioblastoma xenograft - Control 23.3168754
GSM967854U87-EV human glioblastoma xenograft - Control 32.8998239
GSM967855U87-EV human glioblastoma xenograft - Control 42.8224138
GSM967856U87-EV human glioblastoma xenograft - Control 52.8437339
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.95238
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2663650
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8914439
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0739947
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.885139
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8863439
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8141637
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8764138
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8655238